Product review · Updated September 30, 2026
Bubble Super Clear: two study groups and a smaller-looking pore claim
The clinical blemish summary and consumer pore impressions have different participants, durations and endpoints.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Bubble’s Super Clear presents both a clinical blemish summary and consumer observations about how skin looks and feels. Smaller-looking pores appear in the consumer description, alongside numerical comfort findings. The important reading question is which people, duration and endpoint each claim actually concerns.
This review examines the current manufacturer page and the May 3, 2024 US Bubble labeling record obtained on September 30, 2026. The website calls Super Clear a serum; the label describes an emulsion in a 30 mL pump package. These are descriptions associated with the named preparation, not two verified products. No full study report, purchased pump or participant skin was inspected.
In this article
Super Clear has both advertising and label identities
The manufacturer page advertises Super Clear as a 2% salicylic acid serum. Its US label identifies an acne-medication purpose and a use concerning acne and new blemishes. The label’s emulsion terminology and the page’s serum name describe the record differently without establishing two separate preparations.
The 30 mL pump information helps identify the package associated with the posted label. It is not an instruction about an amount to apply. Our format comparison gives product form a place in the evidence reading without treating the name serum as a reason to expect a superior pore result or a particular person’s tolerance.
Thirty-one participants concern blemish appearance
The clinical summary on Bubble’s page reports 31 participants and a one-week observation concerning blemish appearance, size and redness. The manufacturer describes the testing as independent. This review obtained the manufacturer’s summary, rather than the underlying report, so the study design and that independence were not separately audited.
Those endpoints concern blemishes. They do not establish a pore-size score, and the one-week duration cannot be converted into a promised personal response time. Our claims and visible-pores guide separates the named outcome from a broader clearer-skin impression. The clinical description contributes specific information, with its participant group and reported endpoints kept together.
Twenty-one panelists report a different experience
A second manufacturer summary describes 21 consumer panelists observed over two weeks. The page includes agreements about smaller-looking pores and reduced-looking imperfections or redness in that consumer context. This is a separate group and a different evidence description from the 31-participant clinical blemish summary.
The numbers should not be added into a combined 52-person pore study. Nor does the word clinical elsewhere on the page automatically apply to every consumer answer. The Peach Slices moisturizer review is another source-focused reading topic. Its presence here is navigation, not permission to merge those products’ participants, comfort reports or appearance claims.
Eighty-six percent is not the pore percentage
In the two-week consumer account, 86% is attached to skin not feeling flaky and to smoother feel or appearance. The smaller-looking-pore statement does not have a percentage specified in the examined passage. Reporting 86% for pore reduction would therefore move a number from one endpoint to another.
Smoothness and absence of flakiness can be useful observations without being substitutes for a defined pore assessment. A more complete interpretation would need the questionnaire or assessment method for the pore statement and its denominator of responses. The published summary supplies neither here. Our visible-pores and blackheads guide explains why the particular feature observed matters when describing an apparent improvement.
The comfort ingredients do not remove the warning
The posted declaration lists the inactive ingredients alongside the salicylic active; names include colloidal oatmeal, squalane and Centella asiatica extract. An ingredient story can explain what the brand highlights, but it does not establish how every person will feel using the finished serum or how pores will appear.
The label warning retains irritation and dryness as possible when another topical acne medication is involved. That is not negated by supportive ingredients or consumer comfort reports. It also does not supply a personalized compatibility answer. The Naturium serum review offers another individual product reading, with no clinical comparison or transferred ingredient result implied by the link.
The posting date and the observation period differ
The label record is dated May 3, 2024. The study durations in the current product summary describe observation periods, while September 30, 2026 is this review’s source-check date. These dates serve different purposes and do not establish when the formula was last changed or which label an unexamined pump carries.
FDA’s Drug Facts explanation notes that manufacturers sometimes revise labeling and that similar names can describe different active ingredients. Applied to this record, that means an online match identifies the reviewed documents without guaranteeing every package version. The review makes no current-stock or purchased-formula claim, and no laboratory verification of the advertised percentage was obtained.
Pore appearance needs its own assessment description
The most useful follow-up question concerns how pore appearance was assessed in the 21-person consumer group. The Bubble summary gives the group and duration, while leaving the pore scoring method and the detailed report unavailable in the material examined. Those missing details prevent an observer-rated result or a quantified pore response from being inferred.
The published story still has meaningful structure: a one-week clinical blemish account, a separate two-week consumer account and numerical comfort endpoints assigned to their actual subjects. Keeping those parts separate preserves more information than calling everything a clinical pore reduction. It also leaves the evidence open to clarification without promising outcomes or suggesting that the absence of a report proves the serum ineffective.
Sources behind this reading
- Super Clear Acne Treating Serum For All Skin Types ↗Manufacturer exact product, advertising and returned declaration · Checked September 30, 2026
- DailyMed - BUBBLE SUPER CLEAR BLEMISH PREVENTION SERUM- salicylic acid emulsion ↗Exact manufacturer/labeler OTC labeling record, not approval or inspected package · Checked September 30, 2026
- FDA: reading an OTC Drug Facts label ↗Regulator consumer labeling guidance · Checked September 30, 2026